CLINICAL TRIAL: A COMPARISON OF HYDROCHLOROTHIAZIDE AND METOLAZONE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的主要目的是确定哪种药物组合在消除充血性心力衰竭患者体内多余液体方面最有效。 其他目标： 确定呋塞米[Lasix]单独给药以及与氢氯噻嗪[HCTZ]或美托拉宗[Zaroxolyn]联合给药的作用持续时间。 确定联合治疗对激活某些负责体内过量液体的激素的影响。 确定美托拉宗和氢氯噻嗪对预测异常心搏的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of this study is to determine which combination of medications is the most effective in eliminating excess fluids from the body in congestive heart failure patients. Other aims: To determine the duration of action of furosemide [Lasix] by itself and in combination with either hydrochlorothiazide [HCTZ] or metolazone [Zaroxolyn]. To determine the effect of combination therapy on activation of certain hormones responsible for excess fluids in the body. To determine the influence that metolazone and hydrochlorothiazide have on predicting abnormal heart beats.